Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company developing a ground-breaking approach to battling cancer based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Genprex’s Oncoprex has a multimodal mechanism ofaction whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. For more information, visit the company’s website at www.genprex.com.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
The steep cost of healthcare in the U.S. has always been, and is becoming an…
BioMedWire Editorial Coverage: Chronic conditions and rare diseases in the aging population present an urgent…
The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon…
For a long time, the scientific community has known that anything that causes harm to…
Philipson will serve as a strategic advisor to Soligenix, contributing extensive expertise in U.S. economic…
Researchers studying how a common drug, hydralazine, for blood pressure and preeclampsia works at the…